| pubmed-article:11249034 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11249034 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11249034 | lifeskim:mentions | umls-concept:C0346647 | lld:lifeskim |
| pubmed-article:11249034 | lifeskim:mentions | umls-concept:C1521808 | lld:lifeskim |
| pubmed-article:11249034 | lifeskim:mentions | umls-concept:C0079459 | lld:lifeskim |
| pubmed-article:11249034 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:11249034 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:11249034 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:11249034 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:11249034 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:11249034 | pubmed:dateCreated | 2001-3-15 | lld:pubmed |
| pubmed-article:11249034 | pubmed:abstractText | To evaluate the tolerance and efficacy of front-line docetaxel plus gemcitabine treatment in patients with inoperable pancreatic cancer. | lld:pubmed |
| pubmed-article:11249034 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11249034 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11249034 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11249034 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11249034 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11249034 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11249034 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11249034 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11249034 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11249034 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11249034 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:11249034 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:11249034 | pubmed:author | pubmed-author:StathopoulosG... | lld:pubmed |
| pubmed-article:11249034 | pubmed:author | pubmed-author:TsavarisNN | lld:pubmed |
| pubmed-article:11249034 | pubmed:author | pubmed-author:KakolyrisSS | lld:pubmed |
| pubmed-article:11249034 | pubmed:author | pubmed-author:GeorgouliasVV | lld:pubmed |
| pubmed-article:11249034 | pubmed:author | pubmed-author:AravantinosGG | lld:pubmed |
| pubmed-article:11249034 | pubmed:author | pubmed-author:KarabekiosSS | lld:pubmed |
| pubmed-article:11249034 | pubmed:author | pubmed-author:MavroudisDD | lld:pubmed |
| pubmed-article:11249034 | pubmed:author | pubmed-author:AgelakiSS | lld:pubmed |
| pubmed-article:11249034 | pubmed:author | pubmed-author:KouroussisCC | lld:pubmed |
| pubmed-article:11249034 | pubmed:author | pubmed-author:RigatosS KSK | lld:pubmed |
| pubmed-article:11249034 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11249034 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:11249034 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11249034 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11249034 | pubmed:pagination | 101-3 | lld:pubmed |
| pubmed-article:11249034 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:meshHeading | pubmed-meshheading:11249034... | lld:pubmed |
| pubmed-article:11249034 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11249034 | pubmed:articleTitle | Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. | lld:pubmed |
| pubmed-article:11249034 | pubmed:affiliation | Second Department of Internal Medicine, University of Athens, Ippokration Hospital, Greece. | lld:pubmed |
| pubmed-article:11249034 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11249034 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11249034 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:11249034 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:11249034 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11249034 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11249034 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11249034 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11249034 | lld:pubmed |
